NCT04289675View on ClinicalTrials.gov

Multiple Sclerosis: Chi3L1 and Treatment Efficacy

CompletedOBSERVATIONAL
Enrollment

63

Participants

Timeline

Start Date

January 1, 2012

Primary Completion Date

December 1, 2019

Study Completion Date

December 1, 2019

Conditions
Multiple Sclerosis
Interventions
DRUG

Interferon-Beta

Theses drugs have been administered as part of routine care. Biological samples that will be analyzed (blood and cerebrospinal fluid) have been taken as part of routine care.

All Listed Sponsors
lead

Central Hospital, Nancy, France

OTHER

NCT04289675 - Multiple Sclerosis: Chi3L1 and Treatment Efficacy | Biotech Hunter | Biotech Hunter